Literature DB >> 9583073

Maternal CA-125 levels in pregnancy and the puerperium.

M Spitzer1, N Kaushal, F Benjamin.   

Abstract

OBJECTIVE: To determine the levels of CA-125 throughout pregnancy and the puerperium to establish a baseline, thereby indicating what values may be indicative of the pathologic conditions usually associated with elevated CA-125 levels. STUDY
DESIGN: A prospective, longitudinal study was carried out on a consecutive series of pregnant women to determine their CA-125 levels throughout pregnancy and during the puerperium. Blood was drawn at four- to six-week intervals for clinically indicated tests. The residual sera were kept frozen, and subsequently CA-125 measurements were determined by radioimmunoassay.
RESULTS: Of 34 women enrolled in the study, 20 completed the evaluations throughout pregnancy and in the puerperium. The remaining 14 had evaluations for varying portions of their pregnancies but not throughout pregnancy or during the puerperium. The results in these two groups were compared and found not to be statistically significantly different. For the group as a whole, the levels of CA-125 were high, with wide fluctuations in the first trimester; the levels in the early first trimester (five to eight weeks) were particularly high, with a mean of 55.8 and median of 36.2 (range, 6.9-251.2) U/mL. The levels then dropped and remained < 35 U/mL through the rest of pregnancy (including immediately prior to delivery). Another peak, with wide fluctuations, occurred soon after delivery, with a mean of 39.8 and median of 41.9 (range, 10.7-296.7) U/mL. In the late postpartum period (2-10 weeks after delivery) there was a return to baseline levels in all subjects.
CONCLUSION: This study showed that there is a distinct pattern in CA-125 levels during pregnancy and the puerperium. Due to the wide fluctuations in CA-125 levels in very early pregnancy and the immediate postpartum period, CA-125 values during these periods are not useful for clinical correlation with the pathologic conditions known to be associated with elevated levels of CA-125. However, further study is needed to determine whether extreme values in the first trimester or elevated levels after the first trimester are diagnostic or predictive of any conditions related to pregnancy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583073

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  7 in total

1.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 2.  Treatment of recurrent vulvar Paget disease with imiquimod cream: a case report and review of the literature.

Authors:  Esra Tonguc; Tayfun Güngor; Turgut Var; Mustafa Ozat; Izzet Sahin; Levent Sirvan
Journal:  Arch Gynecol Obstet       Date:  2010-08-29       Impact factor: 2.344

Review 3.  Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature.

Authors:  Krystyna Serkies; Ewa Węgrzynowicz; Jacek Jassem
Journal:  Arch Gynecol Obstet       Date:  2011-03-03       Impact factor: 2.344

4.  Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women.

Authors:  Jie Lu; Zhipeng Zheng; Qi Zhang; Guoli Li; Fengying Li; Zhian Le; Jun Huang; Xinyou Xie; Jun Zhang
Journal:  J Clin Lab Anal       Date:  2017-11-30       Impact factor: 2.352

5.  Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.

Authors:  Sileny N Han; Anouk Lotgerink; Mina Mhallem Gziri; Kristel Van Calsteren; Myriam Hanssens; Frédéric Amant
Journal:  BMC Med       Date:  2012-08-08       Impact factor: 8.775

Review 6.  Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors.

Authors:  John A Sandoval; Linda H Malkas; Robert J Hickey
Journal:  Int J Mol Sci       Date:  2012-01-20       Impact factor: 6.208

7.  Ultrasonographic ovarian mass scoring system for predicting malignancy in pregnant women with ovarian mass.

Authors:  Se Jin Lee; Hye Rim Oh; Sunghun Na; Han Sung Hwang; Seung Mi Lee
Journal:  Obstet Gynecol Sci       Date:  2021-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.